Results for:(80 found)
Nov 15, 2012 12:55PM on Top StocksBy InvestorPlace

Next-gen drugs can help power growth and income alike.

Nov 12, 2012 11:26AM on Top StocksBy Minyanville.com

Abbott also reports promising results ahead of a big medical meeting.

Tags: ABTGILD
Nov 9, 2012 3:37PM on Top StocksBy Trefis

The approval of the rheumatoid arthritis treatment will help douse recent concerns about its pipeline.

Tags: ABTJNJPFE
Nov 7, 2012 12:15PM on Top StocksBy Minyanville.com

The pharma wins US approval for a new rheumatoid arthritis pill, but Abbott's existing treatment isn't likely to suffer a meaningful hit to sales anytime soon.

Oct 24, 2012 10:46AM on Top StocksBy TheStreet Staff

The company raises sales guidance while reporting better-than-expected Q3 earnings.

Oct 22, 2012 9:18AM on Top StocksBy Jim Cramer

Tech may be spoiling the party, but old standbys like insurers, banks, retail and oil are holding up nicely.

Oct 19, 2012 11:09AM on Top StocksBy MSN Money Partner

SanDisk is upgraded to 'overweight,' while AMD is downgraded to 'market perform.'

Oct 18, 2012 11:43AM on Top StocksBy Stock Traders Daily

Although Abbott has recently gained on positive trial results, Gilead Sciences remains in the forefront of the market.

VIDEO ON MSN MONEY

DATA PROVIDERS

Copyright © 2014 Microsoft. All rights reserved.

Fundamental company data and historical chart data provided by Morningstar Inc. Real-time index quotes and delayed quotes supplied by Morningstar Inc. Quotes delayed by up to 15 minutes, except where indicated otherwise. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by Morningstar Inc.

MARKET DISPATCHES

No more Dispatches; here's where to find market news

The Market Dispatches column has been discontinued. Here's where to find the latest stock and business news on MSN Money, and the latest from market writer Charley Blaine.

More